指南与共识慢性肾脏病

KDIGO 2026 慢性肾脏病贫血管理临床实践指南执行摘要

Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD).
指南 / 共识 · Kidney Int · 2026-01-01

KDIGO 2026 慢性肾脏病贫血管理指南是对 2012 版指南的更新,覆盖贫血诊断与评估、铁剂治疗铁缺乏与贫血、促红细胞生成素与低氧诱导因子脯氨酰羟化酶抑制剂治疗贫血、以及红细胞输注。指南基于系统综述与 GRADE 方法制定,提供可操作推荐与实践要点,并讨论证据局限性及研究建议。

要点

  • 指南更新覆盖 CKD 贫血的诊断评估、铁剂、ESA 与 HIF-PHI 及红细胞输注。
  • 推荐基于系统综述与 GRADE 方法,附实践要点但后者无系统综述支持。
  • 指南还讨论证据局限性、研究建议及政策与支付影响。

核心结论

  • KDIGO 2026 指南为 CKD 贫血管理提供基于证据的可操作推荐,覆盖诊断、铁剂、ESA、HIF-PHI 及输血。

研究设计与样本

  • 指南由 KDIGO 制定,更新 2012 版,基于系统综述与 GRADE 方法进行证据评价。
  • 制定过程有患者伙伴、医疗提供者与研究者参与,目标是为医患提供实用资源。

关键数值与推荐

  • 推荐强度与证据确定性采用 GRADE 方法分级。
  • 实践要点提供临床建议但不基于系统综述支持。

临床怎么用

  • 临床可依据指南推荐管理 CKD 贫血的诊断评估、铁剂使用、ESA 与 HIF-PHI 治疗及红细胞输注。
  • 实践要点可作为临床参考,但需知晓其无系统综述支持。

局限性

  • 指南讨论了证据的局限性。
  • 指南提供研究建议以填补知识空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Kidney Disease: Improving Global Outcomes (KDIGO) 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) represents an update to the guideline published in 2012. Its scope includes diagnosis and evaluation of anemia; use of iron to treat iron deficiency and anemia in CKD; use of erythropoiesis-stimulating agents and hypoxia-inducible factor-prolyl hydroxylase inhibitors to treat anemia in CKD; and red blood cell transfusions to treat anemia in CKD. The guideline has been developed with patient partners, healthcare providers, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations. The development of this guideline followed an explicit process of evidence review and appraisal based on systematic reviews. The certainty of evidence and strength of recommendations follows the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The guideline also provides practice points that provide clinical advice but are not supported by a systematic review. Limitations of the evidence are discussed. Research recommendations to address gaps in knowledge, and implications for policy and payment, are provided. The guideline targets a broad audience of healthcare providers, affected individuals, and stakeholders involved in the various aspects of anemia and CKD care.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Babitt JL, Berns JS, Bozkurt B, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026. PMID: 41485807. doi:10.1016/j.kint.2025.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。